Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

BACKGROUND: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. METHOD...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gastric Cancer
Asıl Yazarlar: Hescheler, Daniel A., Plum, Patrick S., Zander, Thomas, Quaas, Alexander, Korenkov, Michael, Gassa, Asmae, Michel, Maximilian, Bruns, Christiane J., Alakus, Hakan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Singapore 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305081/
https://ncbi.nlm.nih.gov/pubmed/32107691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-020-01045-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller